News

Nature8d
Shaping membranes into autophagosomes - Nature Cell Biology
The class III phosphatidylinositol 3-kinase (PI (3)KC3) is part of a key complex regulating autophagy. How this complex mechanistically contributes to autophagosome formation remains largely ...
Yahoo Finance20d
Merry Life Launches Global Phase II Trial of TML-6, The First Drug Targeted at Autolysosome pathway for Therapy of Alzheimer's Disease - Yahoo Finance
Merry Life Biomedical Company announces the launch of its global Phase II clinical trial for TML-6, a novel oral small molecule drug targeting early-stage Alzheimer's disease (AD). TML-6 combines ...
The Victoria Advocate21d
Merry Life Launches Global Phase II Trial of TML-6, The First Drug Targeted at Autolysosome pathway for Therapy of Alzheimer's Disease - Victoria Advocate
TAINAN, June 13, 2025 /PRNewswire/ -- Merry Life Biomedical Company announces the launch of its global Phase II clinical trial for TML-6, a novel oral small molecule drug targeting early-stage ...
Yahoo Finance19d
Merry Life Launches Global Phase II Trial of TML-6, The First Drug Targeted at Autolysosome pathway for Therapy of Alzheimer's Disease - Yahoo Finance
Merry Life Biomedical Company announces the launch of its global Phase II clinical trial for TML-6, a novel oral small molecule drug targeting early-stage Alzheimer's disease (AD). TML-6 combines ...
Mena FN20d
Merry Life Launches Global Phase II Trial Of TML-6, The First Drug Targeted At Autolysosome Pathway For Therapy Of Alzheimer's Disease - MENAFN.COM
TAINAN, June 12, 2025 /PRNewswire/ -- Merry Life Biomedical Company announces the launch of its global Phase II clinical trial for TML-6, a novel ...
Finanznachrichten20d
Merry Life Biomedical Company, Ltd.: Merry Life Launches Global Phase II Trial of TML-6, The First Drug Targeted at Autolysosome pathway for Therapy of Alzheimer's Disease
TAINAN, June 13, 2025 /PRNewswire/ -- Merry Life Biomedical Company announces the launch of its global Phase II clinical trial for TML-6, a novel oral small molecule drug targeting early-stage ...
Finanznachrichten27d
Galmed Pharmaceuticals Ltd.: Galmed Announces First Time Results in Oncology Studies: Aramchol Significantly Enhances Bayer's Regorafenib Effect in GI Cancer Models
Aramchol enhanced both flux and autolysosome formation caused by Regorafenib, activating ATM and AMPK and inactivating mTORC1 and mTORC2 pathways.